Literature DB >> 10471170

Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria.

E Eriksson1.   

Abstract

Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruation, and disappear completely within a few days after the onset of the bleeding; in patients with remaining symptoms during the follicular phase, alternative diagnoses should be considered. In a large number of recent trials, serotonin reuptake inhibitors (clomipramine, citalopram, fluoxetine, paroxetine, sertraline) have been shown to reduce the symptoms of PMD much more effectively than placebo; in contrast, non-serotonergic antidepressants (maprotiline, bupropion) appear to be ineffective. Interestingly, the onset of action of clomipramine and selective serotonin reuptake inhibitors (SSRIs) is much shorter when used for PMD than when used for depression, panic disorder, or obsessive-compulsive disorder. Consequently, patients with PMD can restrict the medication to the luteal phase of the cycle. In a recent placebo-controlled trial, intermittent administration of the SSRI citalopram was shown to reduce the symptoms of PMD significantly better than placebo, but also better than continuous administration of the drug. A reasonable interpretation of the latter, unexpected finding is that continuous medication may be associated with a certain development of tolerance than can be avoided by intermittent drug administration. The observation that the symptoms of PMD may be effectively reduced by SSRIs is of considerable clinical importance since previously no effective treatment for this common condition - apart from those disrupting ovarian cyclicity - has been available. It is also of theoretical importance because it constitutes one of the first pharmacological observations supporting the concept that serotonin may dampen irritability and anger in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471170

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  11 in total

1.  Premenstrual syndrome. Evidence-based treatment in family practice.

Authors:  Sue Douglas
Journal:  Can Fam Physician       Date:  2002-11       Impact factor: 3.275

Review 2.  Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management.

Authors:  M Steiner
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

Review 3.  The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications.

Authors:  B L Parry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 4.  Transcription factor AP-2 and monoaminergic functions in the central nervous system.

Authors:  M Damberg
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

Review 5.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

Review 6.  Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?

Authors:  Teri Pearlstein
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Current management of premenstrual syndrome and premenstrual dysphoric disorder.

Authors:  L Born; M Steiner
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 8.081

9.  Treatment of depression associated with the menstrual cycle: premenstrual dysphoria, postpartum depression, and the perimenopause.

Authors:  Ellen W Freeman
Journal:  Dialogues Clin Neurosci       Date:  2002-06       Impact factor: 5.986

10.  Differences in Anxiety-Like Behavior within a Batch of Wistar Rats Are Associated with Differences in Serotonergic Transmission, Enhanced by Acute SRI Administration, and Abolished By Serotonin Depletion.

Authors:  Jakob Näslund; Erik Studer; Robert Pettersson; Melker Hagsäter; Staffan Nilsson; Hans Nissbrandt; Elias Eriksson
Journal:  Int J Neuropsychopharmacol       Date:  2015-02-25       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.